跳至主要内容
临床试验/ACTRN12609000440224
ACTRN12609000440224撤回3 期

A multi-centre, randomised clinical trial examining the effect of Clopidogrel versus Aspirin in addition to optimal medical therapy for heart failure on subsequent heart failure hospitalisation and mortality in patients with class III-IV congestive heart failure.

niversity of Sydney0 个研究点目标入组 1,250 人开始时间: 2009年6月11日最近更新:
适应症

试验速览

阶段
3 期
状态
撤回
入组人数
1,250

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1. Men or women age >18 years
  • 2. Symptomatic heart failure
  • 3. Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) of >600pg/mL
  • OR NT-proBNP >400pg/mLa + Heart Failure (HF) hospitalisation within last 12 months
  • 4. Treatment with an angiotensin converting enzyme (ACE) inhibitor (unless not tolerated) and ongoing treatment with a diuretic
  • 5. Provision of written informed consent

排除标准

  • 1. Contraindication to aspirin or clopidogrel
  • 2. Indication for chronic anti-coagulation
  • 3. Heart failure due to a reversible cause or hypertrophic or infiltrative cardiomyopathy
  • 4. Unstable heart failure or treatment regimen
  • 5. Life-limiting systemic illness
  • 6. Severe chronic obstructive pulmonary disease (COPD) (as evidenced by history of mechanical ventilation, need for home oxygen, or treatment with oral corticosteroids) for more than 3 continuous days within 12 months
  • 7. Conditions that might interfere with protocol compliance

研究者

相似试验